Summary:
An 8-week, randomized, double-blind, placebo and active-controlled, parallel group, dose ranging
study to evaluate the efficacy and safety of 3 doses of CHF 718 pMDI (beclomethasone
dipropionate) in asthmatic subjects
Qualified Participants Must:
• Be Male or female subjects between 18 and 75 years of age
•
Have a Body Mass Index: between 18.5 BMI 35 kg/m2
•
Use of ICS (low/medium dose according to GINA Report 2016) with or without a LABD for 3 months (stable dose in the last 4 weeks) before screening visit
Qualified Participants May Receive:
Pts will be compensated for their time and travel
Study drug will be provided at no cost to you